Kaletra (Lopinavir, Ritonavir)

Kaletra, a protease inhibitor used in antiretroviral therapy, is indicated for the following HIV‑1 related conditions:

• HIV‑1 infection in adults: reduces plasma viral load, improves CD4+ cell counts, and delays disease progression when administered together with a full antiretroviral regimen.
• HIV‑1 infection in children: provides virologic suppression, supports immune system recovery, and helps maintain growth and development as part of pediatric combination therapy.
• Treatment‑experienced HIV‑1 infection: offers an alternative for patients who have developed resistance to other protease inhibitors, contributing to continued viral control in salvage regimens.

• Lopinavir inhibits the HIV‑1 protease enzyme, preventing cleavage of the viral gag‑pol polyprotein and thereby blocking maturation of infectious virions. Ritonavir, present in a low dose, acts as a pharmacokinetic enhancer by strongly inhibiting CYP3A4 metabolism, which raises lopinavir plasma concentrations and prolongs its antiviral activity. This mechanism operates in patients receiving combination antiretroviral therapy.

Kaletra may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate, may lead to dehydration.
• Nausea and vomiting: gastrointestinal discomfort that can affect oral intake.
• Headache: mild to moderate intensity, usually transient.
• Elevated triglycerides: increase in blood lipid levels, may require monitoring.
• Abdominal pain: cramp‑like discomfort in the stomach region.
• Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

• Hepatotoxicity: liver enzyme elevations or hepatitis requiring monitoring.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Severe hypersensitivity reactions: including rash, Stevens‑Johnson syndrome, or anaphylaxis.

When prescribing Kaletra, several precautions should be observed to ensure safe and effective use.

• Pregnancy: Category C; weigh potential benefits against risks and monitor fetal development.
• Liver function: Assess hepatic enzymes before initiation and periodically during therapy.
• Adherence: Emphasize strict dosing schedule to prevent resistance development.
• Drug interactions: Avoid concomitant use of strong CYP3A inducers that may reduce efficacy.
• Lipid monitoring: Check triglyceride and cholesterol levels regularly due to possible elevations.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Kaletra interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A inducers (e.g., rifampin, St. John’s wort): markedly reduce lopinavir concentrations.
• Certain antiarrhythmic agents (e.g., amiodarone): may cause dangerous cardiac effects when combined.
• Concomitant use with other protease inhibitors at high doses: increases risk of toxicity.

Moderate Interactions (Monitor Closely)

• Statins (simvastatin, lovastatin): increased plasma levels may lead to myopathy; dose adjustment required.
• Warfarin: potential alteration of INR; monitor coagulation parameters.
• Anticonvulsants (carbamazepine, phenytoin): may lower lopinavir exposure; consider alternative therapy.